Madrid, 9 March 2011: Sylentis (MC:ZEL) presented the main results of its Phase I trial on safety and tolerance of its product SYL040012; the compound proved to be safe in the trial conditions. These results were presented in an oral communication entitled “Phase I Trial with SYL040012: New RNAi-based treatment for glaucoma”
This new investigational treatment, based on RNA interference, reaches the retina when administered in eye drops. This feature is expected to positively affect patients’ quality of life by eluding the use of current standard treatments administered by intraocular injections. Madrid, 25 September 2017. Sylentis presents, for the first time,
Sylentis has reached the target of recruiting patients for its Phase III trial “HELIX” for the treatment of the signs and symptoms of dry eye disease. We estimate that the results of the trial will be available in the first four months of 2019. Madrid, October 19th, 2018.- Sylentis,
Sylentis reports positive Phase II results with SYL1001 in treating ocular pain related to dry eye syndrome Phase II dose-finding and efficacy trials (SYL1001_II and SYL1001_III) achieved their primary endpoints in terms of ocular pain (VAS) (p<0.016) and hyperaemia reduction with a dose of 1.125% (p<0.0134). SYL1001 was well tolerated
The results of SYL116011 have demonstrated that this treatment reduces the symptoms related to the allergy in 50% to 80%. The ARVO meeting has considered the poster presentation to be of scientific interest, contributing therefore to its release. Around 30% of the worldwide population show allergic symptoms and between 40-80%
HELIX is a Phase III clinical trial started by Sylentis with the investigational new drug SYL1001, based on RNA interference technology (RNAi). The Company has agreed with the U.S. Food and Drug Administration (FDA) on plans for the Phase III clinical program, which is designed to support the submission of
SYL1001 is a compound arising from Sylentis’s research in ophthalmological disorders It is indicated for treating eye discomfort associated with dry eye syndrome SYL1001 is a form of interference RNA (RNAi) SYL1001 inhibits the capsaicin receptor TrpV1, which is expressed on the surface of the eye. Madrid, 27 February
The Company presents the preclinical and clinical results from studies of three molecules for the treatment of dry eye syndrome, macular degeneration and eye allergies. The presentation will take place in the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). That will be
SYL1001 is a new compound arising from Sylentis’s research in ophthalmological disorders It is indicated for treating eye discomfort associated with dry eye syndrome SYL1001 is a form of interference RNA (RNAi) SYL1001 inhibits the capsaicin receptor TrpV1, which is expressed on the surface of the eye
SYL1001 is a compound under investigation for the treatment of dry eye disease. It is a product based on the novel technology RNA interference (RNAi), developed for the treatment of signs and symptoms of this illness. At the Annual Congress of the Association for Research in Vision and Ophthalmology 2017,
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.